Innovation Pharmaceuticals Inc (IPIX)

[makarr]

They didn't shelve the P3. The problem is that P3 trials cost the most by a substantial margin due to the #'s needed for patient enrollment. In this case, would probably be upwards of $30 million, which management does not have at this moment. So though while I consider a P3 B success in ABSSSI a near lock, it is not certain whether this trial will ever take place unless they are able to partner off another compound for some upfront $ to fund it. To me, that's why this thing could truly range between $0-$10 based of Prurisol P2b results. If I had to guess, the increased dose as well as sicker patient population probably skews the likelihood of that to 70%; a 30% chance of total loss of capital is too much for most to stomach.